EPAS1 and hepatocellular carcinoma: For example, Ma et al. showed that sorafenib-induced upregulation of HIF-2α and increased expression of vascular endothelial growth factor (VEGF) and cyclin D1 contribute to the resistance of hypoxic HCC cells to sorafenib.